A phase ii study of carboplatin in nasopharyngeal carcinoma

Kwan H. Chi, Yuan C. Chang, Wing K. Chan, Jacqueline M. Liu, Chi K. Law, Su S. Lo, Chih H. Shu, Shan H. Yen, Jacqueline Whang-Peng, Kuang Y. Chen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This is a phase II study to evaluate the efficacy and toxicity of short-course carboplatin in advanced-stage nasopharyngeal carcinoma (NPC). Thirty-three previously untreated stage III-IV NPC patients were studied. Carboplatin was given as a rapid intravenous injection every 3 weeks. The dose of carboplatin was calculated according to the individual patient’s creatinine clearance and desired platelet nadir of 75,000/μl according to the Egorin formula. Response and toxicity were evaluated. Thirty-two patients were evaluated for response. The median age was 54 years, range 30-70 years. Twenty-four patients had local regional disease and 8 patients had metastatic disease. The median dose of carboplatin given was 415 mg/m2 (range 91-791 mg/m2). Fourteen (44%) patients had a partial response with a 95% confidence interval of 26-62%. Fifteen (47%) patients had stable disease and 3 (9%) progressive disease. The overall median survival rate was not reached at 43 months. Overall toxicity was tolerable. Grade III-IV myelosuppression occurred in 4 (12%) patients. There were no other major toxicity- or treatment-related deaths. We conclude that carboplatin has a significant anticancer effect in advanced NPC. Thus carboplatin combination chemotherapy for the treatment of NPC is worthy of future clinical investigations.

Original languageEnglish
Pages (from-to)203-207
Number of pages5
JournalOncology (Switzerland)
Volume54
Issue number3
DOIs
Publication statusPublished - Jan 1 1997
Externally publishedYes

Fingerprint

Carboplatin
Nasopharyngeal carcinoma
Combination Drug Therapy
Intravenous Injections
Creatinine
Blood Platelets
Survival Rate
Confidence Intervals
Therapeutics

Keywords

  • Carboplatin
  • Nasopharyngeal carcinoma
  • Phase II study

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chi, K. H., Chang, Y. C., Chan, W. K., Liu, J. M., Law, C. K., Lo, S. S., ... Chen, K. Y. (1997). A phase ii study of carboplatin in nasopharyngeal carcinoma. Oncology (Switzerland), 54(3), 203-207. https://doi.org/10.1159/000227689

A phase ii study of carboplatin in nasopharyngeal carcinoma. / Chi, Kwan H.; Chang, Yuan C.; Chan, Wing K.; Liu, Jacqueline M.; Law, Chi K.; Lo, Su S.; Shu, Chih H.; Yen, Shan H.; Whang-Peng, Jacqueline; Chen, Kuang Y.

In: Oncology (Switzerland), Vol. 54, No. 3, 01.01.1997, p. 203-207.

Research output: Contribution to journalArticle

Chi, KH, Chang, YC, Chan, WK, Liu, JM, Law, CK, Lo, SS, Shu, CH, Yen, SH, Whang-Peng, J & Chen, KY 1997, 'A phase ii study of carboplatin in nasopharyngeal carcinoma', Oncology (Switzerland), vol. 54, no. 3, pp. 203-207. https://doi.org/10.1159/000227689
Chi KH, Chang YC, Chan WK, Liu JM, Law CK, Lo SS et al. A phase ii study of carboplatin in nasopharyngeal carcinoma. Oncology (Switzerland). 1997 Jan 1;54(3):203-207. https://doi.org/10.1159/000227689
Chi, Kwan H. ; Chang, Yuan C. ; Chan, Wing K. ; Liu, Jacqueline M. ; Law, Chi K. ; Lo, Su S. ; Shu, Chih H. ; Yen, Shan H. ; Whang-Peng, Jacqueline ; Chen, Kuang Y. / A phase ii study of carboplatin in nasopharyngeal carcinoma. In: Oncology (Switzerland). 1997 ; Vol. 54, No. 3. pp. 203-207.
@article{a4013cc011f54ded973e2698ab6d084c,
title = "A phase ii study of carboplatin in nasopharyngeal carcinoma",
abstract = "This is a phase II study to evaluate the efficacy and toxicity of short-course carboplatin in advanced-stage nasopharyngeal carcinoma (NPC). Thirty-three previously untreated stage III-IV NPC patients were studied. Carboplatin was given as a rapid intravenous injection every 3 weeks. The dose of carboplatin was calculated according to the individual patient’s creatinine clearance and desired platelet nadir of 75,000/μl according to the Egorin formula. Response and toxicity were evaluated. Thirty-two patients were evaluated for response. The median age was 54 years, range 30-70 years. Twenty-four patients had local regional disease and 8 patients had metastatic disease. The median dose of carboplatin given was 415 mg/m2 (range 91-791 mg/m2). Fourteen (44{\%}) patients had a partial response with a 95{\%} confidence interval of 26-62{\%}. Fifteen (47{\%}) patients had stable disease and 3 (9{\%}) progressive disease. The overall median survival rate was not reached at 43 months. Overall toxicity was tolerable. Grade III-IV myelosuppression occurred in 4 (12{\%}) patients. There were no other major toxicity- or treatment-related deaths. We conclude that carboplatin has a significant anticancer effect in advanced NPC. Thus carboplatin combination chemotherapy for the treatment of NPC is worthy of future clinical investigations.",
keywords = "Carboplatin, Nasopharyngeal carcinoma, Phase II study",
author = "Chi, {Kwan H.} and Chang, {Yuan C.} and Chan, {Wing K.} and Liu, {Jacqueline M.} and Law, {Chi K.} and Lo, {Su S.} and Shu, {Chih H.} and Yen, {Shan H.} and Jacqueline Whang-Peng and Chen, {Kuang Y.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1159/000227689",
language = "English",
volume = "54",
pages = "203--207",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - A phase ii study of carboplatin in nasopharyngeal carcinoma

AU - Chi, Kwan H.

AU - Chang, Yuan C.

AU - Chan, Wing K.

AU - Liu, Jacqueline M.

AU - Law, Chi K.

AU - Lo, Su S.

AU - Shu, Chih H.

AU - Yen, Shan H.

AU - Whang-Peng, Jacqueline

AU - Chen, Kuang Y.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - This is a phase II study to evaluate the efficacy and toxicity of short-course carboplatin in advanced-stage nasopharyngeal carcinoma (NPC). Thirty-three previously untreated stage III-IV NPC patients were studied. Carboplatin was given as a rapid intravenous injection every 3 weeks. The dose of carboplatin was calculated according to the individual patient’s creatinine clearance and desired platelet nadir of 75,000/μl according to the Egorin formula. Response and toxicity were evaluated. Thirty-two patients were evaluated for response. The median age was 54 years, range 30-70 years. Twenty-four patients had local regional disease and 8 patients had metastatic disease. The median dose of carboplatin given was 415 mg/m2 (range 91-791 mg/m2). Fourteen (44%) patients had a partial response with a 95% confidence interval of 26-62%. Fifteen (47%) patients had stable disease and 3 (9%) progressive disease. The overall median survival rate was not reached at 43 months. Overall toxicity was tolerable. Grade III-IV myelosuppression occurred in 4 (12%) patients. There were no other major toxicity- or treatment-related deaths. We conclude that carboplatin has a significant anticancer effect in advanced NPC. Thus carboplatin combination chemotherapy for the treatment of NPC is worthy of future clinical investigations.

AB - This is a phase II study to evaluate the efficacy and toxicity of short-course carboplatin in advanced-stage nasopharyngeal carcinoma (NPC). Thirty-three previously untreated stage III-IV NPC patients were studied. Carboplatin was given as a rapid intravenous injection every 3 weeks. The dose of carboplatin was calculated according to the individual patient’s creatinine clearance and desired platelet nadir of 75,000/μl according to the Egorin formula. Response and toxicity were evaluated. Thirty-two patients were evaluated for response. The median age was 54 years, range 30-70 years. Twenty-four patients had local regional disease and 8 patients had metastatic disease. The median dose of carboplatin given was 415 mg/m2 (range 91-791 mg/m2). Fourteen (44%) patients had a partial response with a 95% confidence interval of 26-62%. Fifteen (47%) patients had stable disease and 3 (9%) progressive disease. The overall median survival rate was not reached at 43 months. Overall toxicity was tolerable. Grade III-IV myelosuppression occurred in 4 (12%) patients. There were no other major toxicity- or treatment-related deaths. We conclude that carboplatin has a significant anticancer effect in advanced NPC. Thus carboplatin combination chemotherapy for the treatment of NPC is worthy of future clinical investigations.

KW - Carboplatin

KW - Nasopharyngeal carcinoma

KW - Phase II study

UR - http://www.scopus.com/inward/record.url?scp=0030936676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030936676&partnerID=8YFLogxK

U2 - 10.1159/000227689

DO - 10.1159/000227689

M3 - Article

C2 - 9143400

AN - SCOPUS:0030936676

VL - 54

SP - 203

EP - 207

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -